TITLE

Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy

AUTHOR(S)
Regier, Dean A.; Sunderji, Rubina; Lynd, Larry D.; Gin, Kenneth; Marra, Carlo A.
PUB. DATE
June 2006
SOURCE
CMAJ: Canadian Medical Association Journal;6/20/2006, Vol. 174 Issue 13, p1847
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Patient self-management of long-term oral anticoagulation therapy is an effective strategy in a number of clinical situations, but it is currently not a funded option in the Canadian health care system. We sought to compare the incremental cost and health benefits of self-management with those of physician management from the perspective of the Canadian health care payer over a 5-year period. Methods: We developed a Bayesian Markov model comparing the costs and quality-adjusted life years (QALYs) accrued to patients receiving oral anticoagulation therapy through self-management or physician management for atrial fibrillation or for a mechanical heart valve. Five health states were defined: no events, minor hemorrhagic events, major hemorrhagic events, thrombotic events and death. Data from published literature were used for transition probabilities. Canadian 2003 costs were used, and utility estimates were obtained from various published sources. Results: Self-management resulted in 3.50 fewer thrombotic events, 0.78 fewer major hemorrhagic events and 0.12 fewer deaths per 100 patients than physician management. The average discounted incremental cost of self-management over physician management was found to be $989 (95% confidence interval [CI] $310-$1655) per patient and the incremental QALYs gained was 0.07 (95% CI 0.06-0.08). The cost-effectiveness of self-management was $14 129 per QALY gained. There was a 95% chance that self-management would be cost-effective at a willingness to pay of $23 800 per QALY. Results were robust in probabilistic and deterministic sensitivity analyses. Interpretation: This model suggests that self-management is a cost-effective strategy for those receiving long-term oral anticoagulation therapy for atrial fibrillation or for a mechanical heart valve.
ACCESSION #
21115944

 

Related Articles

  • Selecting an agent for prophylaxis of venous thromboembolism. Myers, John // American Journal of Health-System Pharmacy;12/15/2006, Vol. 63 Issue 24, p2448 

    The article presents a question and answer related to the selection of an agent for prophylaxis of venous thromboembolism. Tips on how to optimize prophylaxis use while controlling the pharmacy expenses are offered. Moreover, the use of dalteparin as the formulary low-molecular-weight heparin at...

  • Heparin-induced thrombocytopenia costly for US hospitals.  // PharmacoEconomics & Outcomes News;1/14/2006, Issue 494, p5 

    The article discusses research being done on the financial impact of heparin-induced thrombocytopenia. It references a study by M. A. Smythe and colleagues published in the November 16, 2005 issue of "Blood" journal. The results show that substituting heparin for alternative anticoagulants...

  • The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia. Nanwa, Natasha; Mittmann, Nicole; Knowles, Sandra; Bucci, Claudia; Selby, Rita; Shear, Neil; Walker, Scott E.; Geerts, William // PharmacoEconomics;2011, Vol. 29 Issue 6, p511 

    Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction associated with heparin exposure. Sunnybrook Health Sciences Centre, a tertiary-care adult academic hospital, has cared for an average of 100 cases of suspected HIT per year. Although the management of suspected HIT...

  • Dalteparin alternative in VTE prevention for patients with cancer.  // PharmacoEconomics & Outcomes News;7/1/2006, Issue 506, p1 

    The article discusses research being done on the use of dalteparin sodium for the prevention of recurrent venous thromboembolism (VTE) in cancer patients. It references a study by G. Dranitsaris et al published in a 2006 issue of "Pharmacoeconomics." A health resource utilisation data was used...

  • Recent Publications on Medications and Pharmacy. Sterling, Jacyntha A. // Hospital Pharmacy;Oct2008, Vol. 43 Issue 10, p846 

    Hospital Pharmacy presents this feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest regarding a broad scope of topics are abstracted monthly. Suggestions or comments may be addressed to Jacyntha Sterling, Drug Information Specialist at...

  • Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in Patients with Acute Coronary Syndrome in Poland: Modelling Study from the Hospital Perspective. Orlewska, Ewa; Budaj, Andrzej; Tereszkowski-Kaminski, Dariusz // PharmacoEconomics;2003, Vol. 21 Issue 10, p737 

    Aim and perspective: To estimate the cost effectiveness of enoxaparin versus unfractionated heparin (UFH) in patients with acute coronary syndrome (ACS) from a Polish hospital perspective. This was intended to facilitate the decision-making process in selecting the most cost-effective treatment...

  • Anticoagulant ADR-related hospitalisations: costs examined.  // PharmacoEconomics & Outcomes News;Aug2014, Vol. 710 Issue 1, p8 

    The article discusses the results of an analysis of data from the Programme de M´edicalisation des Systèmes d'Information database that reveals the cost of anticoagulant therapy-related hospital admissions at over 4400 euros per person in French region of Alsace between 2010 and 2011.

  • Apixaban most cost effective option in the UK.  // PharmacoEconomics & Outcomes News;8/20/2011, Issue 635, p5 

    The article focuses on a study which compared the cost effectiveness of apixaban with enoxaparin sodium and dabigatran etexilate in preventing thromboembolism in patients undergoing total hip or total knee replacement in Great Britain.

  • Novel oral anticoagulants: rapid adoption, large economic impact.  // PharmacoEconomics & Outcomes News;Jun2014, Vol. 705 Issue 1, p8 

    The article reports on U.S. research in 2014 indicating the rapid adoption of novel oral anticoagulants into clinical practice, and its significant healthcare cost implications.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics